From Analysis:
Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream across Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis — or merely correlated with disease pathology? Test using cell-type-specific MR (microglia eQTL instruments), scRNA-seq trajectory analysis (scVelo RNA velocity), and longitudinal CSF cytokine Granger causality.
Claims from this analysis should be evaluated across TREM2, CX3CR1, C1QA, C1QB, C1QC; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.
No AI visual card yet
Theorist position for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
Context: Analytic arms: cell-type-specific MR, scVelo trajectory, longitudinal CSF Granger causality. Exposure genes: TREM2, CX3CR1, C1QA, C1QB, C1QC. Diseases: AD, PD, ALS, MS.
Primary claim: microglial priming as a partially upstream causal node rather than a pure disease-stage correlate is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal re
Skeptic critique for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: microglial activation can be both cause and response; weak eQTL instruments, cell-state drift, and disease-stage confounding could inflate upstream causal estimates.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a de
Domain expert assessment for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence inter
{
"ranked_hypotheses": [
{
"title": "microglial priming as a partially upstream causal node rather than a pure disease-stage correlate requires proximal validation",
"description": "The debate supports carrying forward microglial priming as a partially upstream causal node rather than a pure disease-stage correlate only if a proximal endpoint changes before the late outcome. The decisive validation path is: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses.",
"target
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for CX3CR1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | failed
No comments yet. Be the first to comment!